กำลังโหลด
HKSEHealthcareMedical - Pharmaceuticals
ข้อมูลล่าสุด
HK$4.62
+HK$0.12 · +2.67%
China Resources Pharmaceutical Group Limited, an investment holding company, engages in the manufacture, distribution, and retail of pharmaceutical and other healthcare products in Mainland China and internationally. It operates through four segments: Pharmaceutical Manufacturing, Pharmaceutical Distribution, Pharmaceutical Retail, and Others. The company offers a range of chemical drugs, Chinese medicines, and biological drugs, as well as nutritional and healthcare products for various therapeutic areas, including cardiovascular and cerebrovascular diseases, alimentary tract, endocrine diseases, respiratory diseases, orthopedics, nephrology, rheumatology and immunology, medical nutrition, pediatrics, genitourinary system, dermatological diseases, blood products, therapeutic infusions, antitumor drugs, medicine for cough and cold, anti-infection drugs, and psychoneurosis. It also provides warehousing, logistics, and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical/medical device manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies. In addition, the company is involved in property holding activities, as well as operates retail pharmacies under the Teck Soon Hong brands. It distributes its products under the 999, Dong-E-E-Jiao, Double Crane, Zizhu, Jiangzhong, Boya, and Kun Zhong Yao to hospitals and other medical institutions. The company was formerly known as China Resources Medications Group Limited and changed its name to China Resources Pharmaceutical Group Limited in December 2011. The company was incorporated in 2007 and is based in Wan Chai, Hong Kong. China Resources Pharmaceutical Group Limited is a subsidiary of CRH (Pharmaceutical) Limited.
ข้อมูลล่าสุด
HK$4.62
+HK$0.12 · +2.67%
เวลาในวันใช้เขตเวลาHKT ข้อมูลตลาดอาจล่าช้า
China Resources Pharmaceutical Group Limited, an investment holding company, engages in the manufacture, distribution, and retail of pharmaceutical and other healthcare products in Mainland China and internationally. It operates through four segments: Pharmaceutical Manufacturing, Pharmaceutical Distribution, Pharmaceutical Retail, and Others. The company offers a range of chemical drugs, Chinese medicines, and biological drugs, as well as nutritional and healthcare products for various therapeutic areas, including cardiovascular and cerebrovascular diseases, alimentary tract, endocrine diseases, respiratory diseases, orthopedics, nephrology, rheumatology and immunology, medical nutrition, pediatrics, genitourinary system, dermatological diseases, blood products, therapeutic infusions, antitumor drugs, medicine for cough and cold, anti-infection drugs, and psychoneurosis. It also provides warehousing, logistics, and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical/medical device manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies. In addition, the company is involved in property holding activities, as well as operates retail pharmacies under the Teck Soon Hong brands. It distributes its products under the 999, Dong-E-E-Jiao, Double Crane, Zizhu, Jiangzhong, Boya, and Kun Zhong Yao to hospitals and other medical institutions. The company was formerly known as China Resources Medications Group Limited and changed its name to China Resources Pharmaceutical Group Limited in December 2011. The company was incorporated in 2007 and is based in Wan Chai, Hong Kong. China Resources Pharmaceutical Group Limited is a subsidiary of CRH (Pharmaceutical) Limited.
ช่วงราคารายวัน
ปัจจุบัน HK$4.62
ช่วง 52 สัปดาห์
ปัจจุบัน HK$4.62
เวลาในวันใช้เขตเวลาHKT ข้อมูลตลาดอาจล่าช้า
China Resources Pharmaceutical Group Limited, an investment holding company, engages in the manufacture, distribution, and retail of pharmaceutical and other healthcare products in Mainland China and internationally. It operates through four segments: Pharmaceutical Manufacturing, Pharmaceutical Distribution, Pharmaceutical Retail, and Others. The company offers a range of chemical drugs, Chinese medicines, and biological drugs, as well as nutritional and healthcare products for various therapeutic areas, including cardiovascular and cerebrovascular diseases, alimentary tract, endocrine diseases, respiratory diseases, orthopedics, nephrology, rheumatology and immunology, medical nutrition, pediatrics, genitourinary system, dermatological diseases, blood products, therapeutic infusions, antitumor drugs, medicine for cough and cold, anti-infection drugs, and psychoneurosis. It also provides warehousing, logistics, and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical/medical device manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies. In addition, the company is involved in property holding activities, as well as operates retail pharmacies under the Teck Soon Hong brands. It distributes its products under the 999, Dong-E-E-Jiao, Double Crane, Zizhu, Jiangzhong, Boya, and Kun Zhong Yao to hospitals and other medical institutions. The company was formerly known as China Resources Medications Group Limited and changed its name to China Resources Pharmaceutical Group Limited in December 2011. The company was incorporated in 2007 and is based in Wan Chai, Hong Kong. China Resources Pharmaceutical Group Limited is a subsidiary of CRH (Pharmaceutical) Limited.
ช่วงราคารายวัน
ปัจจุบัน HK$4.62
ช่วง 52 สัปดาห์
ปัจจุบัน HK$4.62
อัตรากำไรที่รายงานในช่วงเวลาที่มีอยู่
รายได้
รายได้จากการดำเนินงาน
รายได้สุทธิ
| รายการ (HKD) | ปีงบประมาณ 2025 | ปีงบประมาณ 2024 | ปีงบประมาณ 2023 | ปีงบประมาณ 2022 | ปีงบประมาณ 2021 |
|---|---|---|---|---|---|
| รายได้ | 300.01B HKD | 274.18B HKD | 270.4B HKD | 223.13B HKD | 193.24B HKD |
| ต้นทุนสินค้าขาย | 250.48B HKD | 230.89B HKD | 228.41B HKD | 188.77B HKD | 164.37B HKD |
| กำไรขั้นต้น | 49.53B HKD | 43.3B HKD | 42.43B HKD | 34.36B HKD | 28.87B HKD |
| การวิจัยและพัฒนา | 3.15B HKD | 2.47B HKD | 2.73B HKD | 1.83B HKD | 1.38B HKD |
| การขาย ทั่วไป และธุรการ | 32.48B HKD | 28.26B HKD | 27.79B HKD | 19.3B HKD | 15.85B HKD |
| ค่าใช้จ่ายในการดำเนินงาน | 35.63B HKD | 30.73B HKD | 30.52B HKD | 24.87B HKD | 21.32B HKD |
| รายได้ดอกเบี้ย | 524.87M HKD | 681.1M HKD | 587.69M HKD | 732.22M HKD | 595.14M HKD |
| ดอกเบี้ยจ่าย | 2.2B HKD | 2.28B HKD | 2.39B HKD | 2.51B HKD | 2.21B HKD |
| ค่าเสื่อมราคาและค่าตัดจำหน่าย | 4.47B HKD | 3.61B HKD | 3.42B HKD | 2.77B HKD | 2.35B HKD |
| รายได้จากการดำเนินงาน | 13.9B HKD | 12.56B HKD | 13.9B HKD | 9.49B HKD | 7.55B HKD |
| รายได้สุทธิ | 4.5B HKD | 3.57B HKD | 4.24B HKD | 3.64B HKD | 3.08B HKD |
ข้อเท็จจริงของบริษัทได้รับการปรับปรุง 14 ต.ค. 2569.
ผลประกอบการล่าสุดที่ประกาศ
ผลประกอบการล่าสุดที่ประกาศ
กองทุนซื้อขายแลกเปลี่ยนที่รายงานความเสี่ยงต่อหุ้นนี้
Vanguard FTSE Emerging Markets ETFVWO15.21M0.01%168.5B USD0.06%US$59.68-0.08%
Vanguard Total International Stock ETFVXUS15.11M0.00%665.7B USD0.05%US$84.54+0.12%
iShares Core MSCI Emerging Markets ETFIEMG11.24M0.01%158.7B USD0.09%US$80.22-0.51%
JPMorgan International Value ETFJIVE6.22M0.15%4.26B USD0.55%US$94.82+0.65%
Vanguard FTSE All-World ex-US ETFVEU2.37M0.00%98.6B USD0.04%US$82.61+0.15%
Avantis Emerging Markets Equity ETFAVEM2.11M0.01%28.14B USD0.33%US$92.82-0.48%
Vident International Equity Strategy ETFVIDI1.93M0.45%444.15M USD0.61%US$39.70+0.78%
Dimensional - Emerging Markets Core Equity 2 ETFDFEM1.57M0.02%9.45B USD0.39%US$39.46-0.53%Vanguard FTSE Emerging Markets ETFVWOVanguard Total International Stock ETFVXUSiShares Core MSCI Emerging Markets ETFIEMGJPMorgan International Value ETFJIVEVanguard FTSE All-World ex-US ETFVEUAvantis Emerging Markets Equity ETFAVEMVident International Equity Strategy ETFVIDIDimensional - Emerging Markets Core Equity 2 ETFDFEMเนื้อหาที่สร้างโดย AI และข้อมูลตลาดที่ล่าช้ามีไว้เพื่อให้ข้อมูลและการศึกษาเท่านั้น ไม่ใช่คำแนะนำการลงทุน